Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Yorichika, Kubota"'
Autor:
Makoto Sumazaki, Fumi Saito, Hideaki Ogata, Miho Yoshida, Yorichika Kubota, Syunsuke Magoshi, Hironori Kaneko
Publikováno v:
Journal of Medical Case Reports, Vol 11, Iss 1, Pp 1-5 (2017)
Abstract Background Breast cancer-related lymphedema often causes cellulitis and is one of the most common complications after breast cancer surgery. Streptococci are the major pathogens underlying such cellulitis. Among the streptococci, the importa
Externí odkaz:
https://doaj.org/article/10b0ef476db343ec97058c4e72643d5b
Publikováno v:
Toho Journal of Medicine. 3(4):142-145
Case Report
Serum p53 antibody (s-p53-Abs) is induced by p53 overexpression in cancer cells. Therefore, residual cancer cells may be the cause of seropositivity even after radical surgery. Only few reports have evaluated perioperative changes an
Serum p53 antibody (s-p53-Abs) is induced by p53 overexpression in cancer cells. Therefore, residual cancer cells may be the cause of seropositivity even after radical surgery. Only few reports have evaluated perioperative changes an
Autor:
Yorichika, Kubota, Hideaki, Ogata, Seiko, Otsuka, Akiko, Kuwajima, Fumi, Saito, Hideaki, Shimada
Publikováno v:
Toho Journal of Medicine. 3(4):125-130
Original Article
Background: Ras-like GTPases, RalA, and RalB, are members of the Ras superfamily of small GTPases. Their aberrant activation is a major cause of human tumorigenesis induced by oncogenic Ras. Serum anti-RalA antibodies (s-RalA-Ab
Background: Ras-like GTPases, RalA, and RalB, are members of the Ras superfamily of small GTPases. Their aberrant activation is a major cause of human tumorigenesis induced by oncogenic Ras. Serum anti-RalA antibodies (s-RalA-Ab
Autor:
Yorichika, Kubota, Hideaki, Shimada, Shunsuke, Magoshi, Fumi, Saito, Tadatoshi, Osaku, Tetsuo Nemoto, Hideaki, Ogata, Hironori, Kaneko
Publikováno v:
Toho Journal of Medicine. 2(1):22-25
Case Report
Serum p53 antibody (s-p53-Ab) is the most recently developed biomarker for breast cancer. Only a few studies have evaluated perioperative s-p53-Ab titers in patients with breast cancer. S-p53-Ab titers were monitored for over 4 years
Serum p53 antibody (s-p53-Ab) is the most recently developed biomarker for breast cancer. Only a few studies have evaluated perioperative s-p53-Ab titers in patients with breast cancer. S-p53-Ab titers were monitored for over 4 years
Autor:
Syunsuke Magoshi, Miho Yoshida, Fumi Saito, Makoto Sumazaki, Hironori Kaneko, Yorichika Kubota, Hideaki Ogata
Publikováno v:
Journal of Medical Case Reports
Journal of Medical Case Reports, Vol 11, Iss 1, Pp 1-5 (2017)
Journal of Medical Case Reports, Vol 11, Iss 1, Pp 1-5 (2017)
Breast cancer-related lymphedema often causes cellulitis and is one of the most common complications after breast cancer surgery. Streptococci are the major pathogens underlying such cellulitis. Among the streptococci, the importance of the Lancefiel
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 74:1193-1197
Autor:
Shinsaku Kanazawa, Kenichi Maruyama, Tetsuo Nemoto, Yorichika Kubota, Kazutoshi Shibuya, Tsuneyoshi Yakuwa, Yukio Mitsuzuka, Fumi Saito, Hironori Kaneko, Hideaki Ogata
Publikováno v:
Choonpa Igaku. 40:167-174
Autor:
Fumi Saito, Shunsuke Magoshi, Yorichika Kubota, Hideaki Ogata, Tetsuo Nemoto, Chikako Hasegawa, Hironori Kaneko, Shinsaku Kanazawa
Publikováno v:
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons). 37:239-243
Autor:
Yoko Nagai, Fumi Saito, Shunsuke Magoshi, Shinsaku Kanazawa, Hideaki Ogata, Yorichika Kubota, Aki Mitsuda, Hironori Kaneko
Publikováno v:
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons). 35:735-738
Autor:
Kazuhiko Natori, Shinsaku Kanazawa, Yorichika Kubota, Yoshihiro Kikuchi, Tadatoshi Osaku, Nobuyuki Shiraga, Masahiro Kobayashi, Hideaki Ogata, Fumi Saito, Shunsuke Magoshi, Hironori Kaneko, Yoshie Murakami
Publikováno v:
Medicine
Triple-negative breast cancer (TNBC) is aggressive, with high risk of visceral metastasis and death. A substantial proportion of patients with TNBC is associated with BRCA mutations, implying that these tumors are sensitive to DNA-damaging agents. We